Caffeoyl pyrrolidine derivative LY52 inhibits tumor invasion and metastasis via suppression of matrix metalloproteinase activity

Anticancer Research

Volumn 26, Issue 5 A, 2006, Pages 3573-3578

  Qu, Xianjun ^a   Yuan, Yunxia ^a   Xu, Wenfang ^a   Chen, Minghui ^a   Cui, Shuxiang ^b   Meng, Hong ^b   Li, Yan ^c   Makuuchi, Masatoshi ^c   Nakata, Munehiro ^a,d   Tang, Wei ^a,c  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TOKYO   (Japan)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

Caffeoyl pyrrolidine derivative; LY52; Matrix metalloproteinase; Metastasis; Tumor invasion

Indexed keywords

CAFFEOYLPYRROLIDINE DERIVATIVE; GELATINASE A; GELATINASE B; LY 52; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; ENZYME REPRESSION; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ZYMOGRAPHY;

ANIMALS; CAFFEIC ACIDS; CARCINOMA, LEWIS LUNG; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; LAMININ; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PROTEOGLYCANS; PYRROLIDINES; TUMOR CELLS, CULTURED;

EID: 33750689843     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rundhaug JE: Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9: 267-285, 2005.
2. Ikejiri M, Bernardo MM, Bonfil RD et al: Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 280: 33992-34002, 2005.
3. Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11: 1696-1701, 2006.
4. Giannelli G, Falk-Marzillier J, Schiraldi O et al: Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277: 225-228, 1997.
5. Stamenkovic I: Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 10: 415-433, 2000.
6. Deryugina EI, Ratnikov B, Monosov E et al: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 265: 209-223, 2001.
7. Heathfield TF, Onnerfjord P, Dahlberg L and Heinegard D: Cleavage of fibromodulin in cartilage explants involves removal of the N-terminal tyrosine sulfate-rich region by proteolysis at a site that is sensitive to matrix metalloproteinase-13. J Biol Chem 279: 6286-6295, 2004.
8. Gonnella NC, Li YC, Zhang X and Paris CG: Bioactive conformation of a potent stromelysin inhibitor determined by X-nucleus filtered and multidimensional NMR spectroscopy. Bioorg Med Chem 5: 2193-2201, 1997.
9. Li YL and Xu WF: Design, synthesis, and activity of caffeoyl pyrrolidine derivatives as potential gelatinase inhibitors. Bioorg Med Chem 12: 5171-5180, 2004.
10. Li X, Li Y and Xu W: Design, synthesis, and evaluation of novel galloyl pyrrolidine derivatives as potential anti-tumor agents. Bioorg Med Chem 14: 1287-1293, 2006.
11. Qu XJ, Yang JL, Russell PJ and Goldstein D: Changes in epidermal growth factor receptor expression in human bladder cancer cell lines following interferon-alpha treatment. J Urol 172: 733-738, 2004.
12. Baragi VM, Shaw BI, Renkiewicz RR et al: A versatile assay for gelatinases using succinylated gelatin. Matrix Biol 19: 267-273, 2000.
13. Tian B, Li Y, Ji XN et al: Basement membrane proteins play an active role in the invasive process of human hepatocellular carcinoma cells with high metastasis potential. J Cancer Res Clin Oncol 131: 80-86, 2005.
14. Tong TM, Rajah TT, Zang XP and Pento JT: The effect of antiestrogens on TGF-beta-mediated chemotaxis of human breast cancer cells. Anticancer Res 22: 103-106, 2002.
15. Chan BC, Li Q, Chow SK et al: BRE enhances in vivo growth of tumor cells. Biochem Biophys Res Commun 326: 268-273, 2005.
16. Kontogiorgis CA, Papaioannou P and Hadjipavlou-Litina DJ: Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q) SARs results. Curr Med Chem 12: 339-355, 2005.
17. Agrawal S, Anderson P, Durbeej M et al: Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 203: 1007-1019, 2006.
18. Toda D, Ota T, Tsukuda K et al: Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells. Anticancer Res 26: 129-134, 2006.
19. Belotti D, Paganoni P, Manenti L et al: Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 63: 5224-5229, 2003.
20. Huang S, Van Arsdall M, Tedjarati S et al: Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 94: 1134-1142, 2002.
21. Amano S, Ogura Y, Akutsu N et al: Protective effect of matrix metalloproteinase inhibitors against epidermal basement membrane damage: skin equivalents partially mimic photoageing process. Br J Dermatol 153: 37-46, 2005.
22. Levitt NC, Eskens F A, O'Byrne KJ et al: Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 7: 1912-1922, 2001.
23. Eatock M, Cassidy J, Johnson J et al: A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. Cancer Chemother Pharmacol 55: 39-46, 2005.
24. Baba M, Itoh K and Tatsu M: Glycine-extended gastrin induces matrix metalloproteinase-1- and -3-mediated invasion of human colon cancer cells through type I collagen gel and Matrigel. Int J Cancer 111: 23-31, 2004.
25. Feng X, Danqing S and Yongsu Z: Discussion of the inhibition of angiogenesis and its mechanism. In: Progress of Anti-neoplasm-drugs and Chemotherapy. Beijing Science Publ Corp., p. 243, 2001.